Prevalence of Rheumatic Diseases in Adult Population in Spain (EPISER 2016 Study): Aims and Methodology

Seoane‐Mato, Daniel; Sánchez-Piedra, Carlos; Silva-Fernández, Lucía; Sivera, Francisca; Blanco, Francisco J.; Pérez-Ruiz, Fernando; Juan-Mas, Antonio; Pego‐Reigosa, José María; Narváez, Javier; Martí, Neus Quilis; Verdu, R; Antón-Pagés, Fred; Vila, V.; Courel, L. Garrido; Amo, Natividad del Val del; Zudaire, I. Paniagua; Sturchio, Gustavo Añez; Varo, Fermín Medina; Tudela, María del Mar Ruiz; Pérez, Antonio Romero; Ballina, Javier; García, Anahy Brandy; Canales, Dolores Fábregas; Gayá, Teresa Font; Ferrer, Carolina Bordoy; Álvarez, Beatriz González; Hernández, Laura Casas; Reyes, Fátima Álvarez; Sánchez, Mónica Delgado; Dubois, Cristina Martínez; Sánchez-Fernández, Simón; Vargas, Luisa Marena Rojas; Morales, Paula Virginia García; Olivé, Alejandro; Muñoz, P. Rubio; Larrosa, M.; Ricos, Noemí Navarro; Martín, Eduard Graell; Chamizo, E.; Chaparro, Lara Chaves; Herrera, Sara Rojas; Dolset, Jordi Pons; Ostariz, Miguel Ángel Polo; Garrido, Susana Ruiz-Alejos; Macía-Villa, Cristina; Valenciano, Ana Cruz; Gómez, María Luisa González; Valle, Mercedes Morcillo; Sánchez, Deseada Palma; Martínez, María José Moreno; González, Marta Mayor; Buruaga, Joana Atxotegi Sáenz de; Onaindia, Irati Urionagüena; Cáceres, B. A. Blanco; Dı́az-González, Federico; Bustabad, Sagrario

doi:10.1016/j.reumae.2018.10.004

Cited by 28 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CI was defined as the number of patients with IAD that met inclusion and exclusion criteria that were admitted to the COVID‐19 Patient Flow during the enrolment period divided by the total number of patients with IAD in the HRUM Emergency Department health influence area at the start of the enrolment period. The number of patients with IAD at risk at the beginning of the period was estimated based on the total population with 18 years and older served by the HRUM Emergency Department, which according to the most recently available official epidemiological reports is 302 556 persons, 17‐19 and on the estimated prevalence (CI 95%) of RA (0.82 [0.59‐1.15]), PsA (0.58 [0.38‐0.87]), and ankylosing spondylitis (0.26 [0.14‐0.49]), in Spain EPISER study 20,21 . The CFR was estimated based on the number of deaths during the enrolment period.…”

Section: Methodsmentioning

confidence: 99%

Incidence and case fatality rate of COVID‐19 in patients with inflammatory articular diseases

et al. 2020

View full text Add to dashboard Cite

Objective To describe the incidence and fatality of coronavirus disease 2019 (COVID‐19) and identify risk factors to fatality in patients with inflammatory articular diseases (IAD). Methods This is a cross‐sectional observational study of IAD patients and COVID‐19 with controls matched for age, sex, and RT‐PCR. A control group was used to compare the cumulative incidence (CI) and case fatality rate (CFR). The main outcomes of the study were CI and CFR. Other variables included comorbidities, treatments, and characteristics of the COVID‐19. Multiple logistic regression analysis was performed to investigate risk factors for fatality in patients with IAD. Results Of the 1537 patients who fulfilled the inclusion criteria, 23/1537 (1.49%) had IAD 13 (0.8%) had rheumatoid arthritis (RA), 5 psoriatic arthritis (PsA) (0.3%) and 5 axial spondyloarthritis (0.3%). There were no significant differences in CI of COVID‐19 and CFR in patients with IAD compared with COVID‐19 patients without IAD. In RT‐PCR positive patients, the CI of COVID‐19 in PsA and AS was higher. Of the 23 IAD patients, 2 RA patients (8.6%) died. The patients did no show characteristics of the COVID‐19 disease different from the population. In multivariate analysis, the factor associated with fatality in patients with IAD was older age (OR [95% CI], 1.1 [1.0‐1.2]). Conclusion COVID‐19 CI, fatality rate and other features do not seem to be increased in IAD patients. Older age was associated with fatality in patients with IAD.

show abstract

Section: Methodsmentioning

confidence: 99%

Incidence and case fatality rate of COVID‐19 in patients with inflammatory articular diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The clinical diagnostic criteria for hyperuricemia are SUA >420 µmol/l in males and SUA >360 µmol/l in females (5). Recent studies have shown that following changes to the structure of the human diet, the incidence of hyperuricemia in the world is increasing (6)(7)(8), and the age of onset of hyperuricemia is decreasing (9,10).…”

Section: Introductionmentioning

confidence: 99%

Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia

Cai

Deng

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

At present, the treatment of hyperuricemia is designed primarily to decrease the production of uric acid using xanthine oxidase inhibitors; however, the therapeutic effect is not satisfactory. Therefore, the key to the successful treatment of hyperuricemia is to increase the excretion of uric acid. The aim of present study was to construct uricase-expressing genetically engineered bacteria and analyze the effects of these engineered bacteria on the lowering of uric acid levels in a rat model of hyperuricemia. The uricase expression vector was constructed by gene recombination technology and transfected into Escherichia coli. The expression and activity of uricase were analyzed by SdS-PAGE analysis and Bradford assay. The water consumption, food intake, body weight, eosinophil count and intestinal histology, in addition to the levels of serum uric acid (SUA) and allantoin in the feces of the rats, were assessed. The intestinal contents of the rats were analyzed by 16S rdNA sequencing technology. The results demonstrated that uricase-expressing genetically engineered bacteria secreted active uricase. All rats exhibited a natural growth trend during the entire experiment, and the SUA of hyperuricemic rats treated with uricase-expressing engineered bacteria was significantly decreased. In conclusion, these results indicate that uricase secreted by recombinant uricase-expressing genetically engineered bacteria served an important role in decreasing SUA levels in a rat model of hyperuricemia.

show abstract

“…The at-risk population was estimated based on national census data provided by the Spanish Statistics Institute, and the prevalence rates of SpA were taken as 0.84% overall, 1.13% in men and 0.54% in women, these prevalence rates are corresponding to the sum of the rates for AS and PsA estimated in the Spanish epidemiological study EPISER. 22 …”

Section: Methodsmentioning

confidence: 99%

Trends in amyloidosis in spondyloarthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999–2015)—TREND-EspA study

et al. 2021

View full text Add to dashboard Cite

ObjectiveTo assess the incidence of amyloidosis and trends therein in patients with spondyloarthritis (SpA) over a long period (17 years).MethodsAn observational retrospective population-based matched cohort study was conducted. All the admissions of patients with SpA, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), arthritis associated with inflammatory bowel disease (SpA-IBD) and reactive arthritis (ReA), reported between 1999 and 2015, were analysed and a control group matched by age, sex and year of admission was selected. Incidence rates for amyloidosis were calculated. Generalised linear models were used for trend analysis and unconditional logistic regression for calculating crude and adjusted ORs (AOR) to assess the association between amyloidosis and SpA.ResultsThe study database contained data on 107 140 admissions in each group. Between 1999 and 2015, 792 patients in the SpA cohort (0.7% of all admissions) had a diagnosis of amyloidosis versus 68 in the non-SpA cohort (0.1%) (p<0.001). From 1999 to 2015, incidence rates of amyloidosis tended to decrease in the SpA cohort (−4.63%/year overall), while they increased in the Non-SpA cohort (+10.25%/year overall). We found strong associations of amyloidosis with all SpAs (AOR 10.4; 95% CI 8.2 to 13.3) and with each type studied (AORs 10.05 (7.84 to 12. 88) for AS, 9.5 (7.3 to 12.4) for PsA, 22.9 (16.6 to 31.7) for SpA-IBD and 10.1 (6.1 to 16.7) for ReA).ConclusionsIncidence of amyloidosis among patients with SpA has strongly decreased in Spain. Amyloidosis is most strongly associated with SpA-IBD while the strength of association with PsA and ReA is similar to that with AS.

show abstract

Prevalence of Rheumatic Diseases in Adult Population in Spain (EPISER 2016 Study): Aims and Methodology

Cited by 28 publications

References 28 publications

Incidence and case fatality rate of COVID‐19 in patients with inflammatory articular diseases

Incidence and case fatality rate of COVID‐19 in patients with inflammatory articular diseases

Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia

Trends in amyloidosis in spondyloarthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999–2015)—TREND-EspA study

Contact Info

Product

Resources

About